Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Accounts Payables (2016 - 2025)

Iovance Biotherapeutics has reported Accounts Payables over the past 13 years, most recently at $22.2 million for Q4 2025.

  • Quarterly results put Accounts Payables at $22.2 million for Q4 2025, down 19.45% from a year ago — trailing twelve months through Dec 2025 was $22.2 million (down 19.45% YoY), and the annual figure for FY2025 was $22.2 million, down 19.45%.
  • Accounts Payables for Q4 2025 was $22.2 million at Iovance Biotherapeutics, down from $31.2 million in the prior quarter.
  • Over the last five years, Accounts Payables for IOVA hit a ceiling of $33.1 million in Q4 2023 and a floor of $19.3 million in Q3 2023.
  • Median Accounts Payables over the past 3 years was $29.8 million (2023), compared with a mean of $28.2 million.
  • Peak annual rise in Accounts Payables hit 10.85% in 2025, while the deepest fall reached 19.45% in 2025.
  • Iovance Biotherapeutics' Accounts Payables stood at $33.1 million in 2023, then fell by 16.95% to $27.5 million in 2024, then dropped by 19.45% to $22.2 million in 2025.
  • The last three reported values for Accounts Payables were $22.2 million (Q4 2025), $31.2 million (Q3 2025), and $32.0 million (Q2 2025) per Business Quant data.